Unyango lwesondlo luhlala lusetyenziswa kunye ne-lymphoma subtypes ezininzi ngenjongo yokugcina i-lymphoma ixolelwe ixesha elide.
Yintoni unyango lwesondlo?
Unyango lwesondlo lubhekiselele kunyango oluqhubekayo emva kokuba unyango lokuqala lufake i-lymphoma kwi-remission (i-lymphoma iyancipha okanye iphendule kunyango). Injongo kukwenza uxolelo luhlale ixesha elide kangangoko kunokwenzeka. Olona hlobo luqhelekileyo lonyango olusetyenziswayo kulondolozo lune-antibody (efana ne-Rituximab okanye i-Obinutuzumab).
I-Chemotherapy ngamanye amaxesha isetyenziswa njengonyango lokugcinwa kwabantwana kunye nabantu abancinci i-lymphoblastic lymphoma. Ngokuqhelekileyo ziqalwa kwiinyanga ezi-6 zokuqala emva konyango lokuqala ukugcina i-lymphoma ingaqhubeli phambili okanye iphinde iphindeke.
Ingaba unyango lwesondlo luya kuhlala ixesha elingakanani?
Ngokuxhomekeke kuhlobo lwe-lymphoma kunye neziyobisi ezisetyenzisiweyo, unyango lwesondlo lunokuhlala iiveki, iinyanga, okanye iminyaka. Ayizizo zonke izigulane ezicetyiswayo ukuba zibe nonyango lwesondlo ukuba i-lymphoma yabo iphantsi kolawulo emva konyango lokungeniswa. Kufunyenwe ukuba kunenzuzo kwiintlobo ezithile ze-lymphoma.
I-Rituximab yi-antibody ye-monoclonal edla ngokucetyiswa njengonyango lolondolozo kwizigulane ezineendlela ezininzi ezahlukeneyo ze-non-Hodgkin lymphoma (NHL). Ezi zigulana zihlala zifumana i-rituximab njengenxalenye yonyango lwabo lokungeniswa, ngokuqhelekileyo ludibene nechemotherapy (ebizwa ngokuba yi-chemoimmunotherapy).
Ukuba i-lymphoma iphendula kunyango lokuqala, i-rituximab inokucetyiswa ukuba iqhutyelwe 'njengonyango lwesondlo'. I-rituximab kwisigaba sokulondoloza ilawulwa kanye kwiinyanga ezi-2-3. I-Rituximab okwangoku inikezelwa ixesha elide leminyaka emi-2, nangona iimvavanyo zeklinikhi zivavanya ukuba kukho nayiphi na inzuzo kunyango lolondolozo oluqhubeka ixesha elide. Kunyango lwesondlo, i-rituximab inokunikwa nge-intravenously (ngenaliti kwi-vein) okanye i-subcutaneously (ngenaliti phantsi kwesikhumba).
Kungenjalo, i-Obinutuzumab (i-Gazyva) yenye i-antibody ye-monoclonal ekwasetyenziselwa ukugcinwa kwezigulane ezine-follicular lymphoma post chemotherapy. I-Obinutuzumab ilawulwa rhoqo kwiinyanga ezi-2 iminyaka emi-2.
Ngubani ofumana unyango lwesondlo?
I-rituximab yokugcina isetyenziswe ikakhulu kwii-subtypes ze-NHL ezingenzi lutho ezifana ne-follicular lymphoma. Unyango lwesondlo ngoku lujongwe kwezinye iindidi ze-lymphomas. Abantwana kunye nabantu abancinci abane-lymphoblastic lymphoma banokunikwa unyango lwesondlo kunye ne-chemotherapy ukukhusela i-lymphoma yabo ibuyele kwakhona. Le yikhosi encinci ye-chemotherapy.
Ziziphi iingenelo zonyango lwesondlo?
Ukuba nonyango lwesondlo kunye ne-rituximab okanye i-Obinutuzumab inokunyusa ubude bokuxolelwa kwizigulane ezine-follicular okanye i-mantle cell lymphoma. Uphando lubonise ukuba ukubuyela kwakhona kunokulibaziseka okanye kuthintelwe, ngokuqhubeka okanye 'ukugcina' unyango nge-rituximab ngexa izigulane zixolile. Injongo kukuthintela izigulane eziye zasabela kunyango lokuqala ukuba ziphinde zibuyele ngelixa ekugqibeleni ziphucula ukusinda jikelele. EOstreliya, oku kuxhaswa ngemali kuphela esidlangalaleni (PBS) ye-rituximab kwi-follicular lymphoma.
Imingcipheko yonyango lwesondlo
Nangona amachiza asetyenziselwa unyango lolondolozo ngokubanzi aneziphumo ebezingalindelekanga ezimbalwa kunendibaniselwano yechemotherapy, izigulana zisenokufumana iziganeko ezimbi kolu nyango. Ugqirha uya kuthathela ingqalelo zonke iimeko zeklinikhi phambi kokumisela unyango lokuqala kunye nokuba isigulane siya kuxhamla kunyango lwesondlo ngokuchasene nolunye unyango okanye 'jonga kwaye ulinde'.
Uninzi lwezigulana azinazo iziphumo ebezingalindelekanga ezininzi ezinengxaki ngelixa zikwi-rituximab. Nangona kunjalo, akusoloko kufanelekile ukuba wonke umntu afumane unyango lwesondlo. Ezinye zeziphumo ebezingalindelekanga zolondolozo lweRituximab zezi:
- Ukuphendula ngokuchaseneyo
- Ukunciphisa iziphumo kwiiseli zegazi
- Intloko ebuhlungu okanye iimpawu zomkhuhlane
- Ukukhathala okanye ukhathala
- Ulusu lutshintsha njengerhashalala
Unyango oluphantsi kophando njengonyango lolondolozo
Uninzi lwabantu olutsha kunye nonyango oludibeneyo luyalingwa kwihlabathi jikelele ukuze lusetyenziswe kunyango lwe-lymphoma. Amanye ala machiza aquka:
- Bortezomib (Velcade)
- Brentuximab vedotin (Adcetris)
- ILenalidomide (Revlimid)
- I-Vorinostat (eZolinza)
Uphando lwezeNzululwazi luyakhula ngokuqhubekayo. Ukhetho lonyango lunokutshintsha njengoko unyango olutsha lufunyaniswa kunye neendlela zonyango eziphuculweyo.
Inkcukacha ezithe vetshe
Ungafikelela kulwazi olongezelelweyo malunga nonyango lwesondlo olufumanayo ngokulandela amakhonkco angezantsi:
